|
Match
|
Document |
Document Title |
|
|
US20090286753 |
NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAS
The invention relates to ribonucleic acids and oligonucleotide probes useful for detection and analysis of microRNAs and their target mRNAs, as well as small interfering RNAs (siRNAs).
|
|
|
US20090285843 |
EPITOPE SEQUENCES
Disclosed herein are polypeptides, including epitopes, clusters, and antigens. Also disclosed are compositions that include said polypeptides and methods for their use.
|
|
|
US20090285784 |
DSRNA As Insect Control Agent
The present invention concerns methods for controlling insect infestation via RNAi-mediated gene silencing, whereby the intact insect cell(s) are contacted with a double-stranded RNA from outside...
|
|
|
US20090264381 |
NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 151P3D4 USEFUL IN TREATMENT AND DETECTION OF CANCER
A novel gene (designated 151P3D4) and its encoded protein, and variants thereof, are described wherein 151P3D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly...
|
|
|
US20090247482 |
50 Human Secreted Proteins
The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells,...
|
|
|
US20090239816 |
Multitargeting Interfering RNAs And Methods Of Their Use And Design
Interfering RNA molecules are now designed and produced with specificity for multiple binding sequences present in distinct genetic contexts in one or more pre-selected target RNA molecules and are...
|
|
|
US20090239815 |
Novel human microRNAs associated with cancer
The invention provides new sequences for human microRNAs associated with cancer which may be used as molecular markers for cancer diagnostics or as therapeutic targets or agents.
|
|
|
US20090227533 |
miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention
The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-34, using miR-34 to modulate a gene or gene pathway, using this profile in...
|
|
|
US20090215711 |
Novel compositions and methods in cancer
The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide...
|
|
|
US20090215709 |
Methylation markers for diagnosis and treatment of cancers
Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting...
|
|
|
US20090214542 |
Novel therapeutic targets in cancer
The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide...
|
|
|
US20090209479 |
THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS
Aspects of the invention include 2′ protected nucleoside monomers that are protected at the 2′ site with thiocarbon protecting groups. Thiocarbon protecting groups of interest include...
|
|
|
US20090209478 |
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE HAMP GENE
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is...
|
|
|
US20090203635 |
HXAAA01 Polynucleotides
The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells,...
|
|
|
US20090203588 |
Outcome prediction and risk classification in childhood leukemia
Genes and gene expression profiles useful for predicting outcome, risk classification, cytogenetics and/or etiology in pediatric acute lymphoblastic leukemia (ALL). OPAL1 is a novel gene associated...
|
|
|
US20090192118 |
TAK1-D MEDIATED INDUCTION OF CELL DEATH IN HUMAN CANCER CELLS BY SPECIFIC SEQUENCE SHORT DOUBLE-STRANDED RNAS
The splicing variant D of the TAK1 gene is activated by short double-stranded RNAs in a sequence specific manner. Activation of TAK1-D leads to the downstream activation of the p38 MAPK and of...
|
|
|
US20090192117 |
COMPOSITIONS AND METHODS FOR THE SUPPRESSION OF TARGET POLYNUCLEOTIDES FROM LYGUS
Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a pest from the Lygus genus, they are capable of decreasing the expression of a...
|
|
|
US20090192114 |
miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-10, using miR-10 to modulate a gene or gene pathway, using this profile in...
|
|
|
US20090192113 |
Interfering RNA Duplex Having Blunt-Ends and 3`-Modifications
The present invention relates to double-stranded RNA compounds with at least one blunt end comprising at least one 3′-end of formula
wherein
X is O or S R 1 and R 2 are independently...
|
|
|
US20090192112 |
COMPOSITIONS AND METHODS FOR TREATING CANCER
The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target ATDC (TRIM29) expression in cancer...
|
|
|
US20090192111 |
miR-124 Regulated Genes and Pathways as Targets for Therapeutic Intervention
The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-124, using miR-124 to modulate a gene or gene pathway, using this profile in...
|
|
|
US20090192110 |
RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION
The present invention relates to oligomeric compounds (oligomers), which target PIK3CA mRNA in a cell, leading to reduced expression of PIK3CA. Reduction of PIK3CA expression is beneficial for the...
|
|
|
US20090192109 |
Compositions for diagnosis and therapy of diseases associated with aberrant expression of Kremen and/or Wnt
The present invention relates to a composition useful for the diagnosis and therapy of diseases associated with aberrant expression of the gene encoding the receptor Kremen 1 and/or Kremen 2 e.g....
|
|
|
US20090192108 |
Gene overexpressed in cancer
Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding...
|
|
|
US20090192107 |
Breast Cancer Markers
A method for the detection of the presence of or the risk of cancer in a patient, comprising, with reference to a normal control, the step of: (i) detecting the expression level of a gene...
|
|
|
US20090192105 |
RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
This invention relates to compounds, compositions, and methods useful for modulating intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) molecules....
|
|
|
US20090192104 |
RNA INTERFERENCE MEDIATED INHIBITION OF HYPOXIA INDUCIBLE FACTOR 1 (HIF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
This invention relates to compounds, compositions, and methods useful for modulating hypoxia inducible factor (e.g., HIF1) gene expression using short interfering nucleic acid (siNA) molecules....
|
|
|
US20090192103 |
Multitargeting Interfering RNAs Having Two Active Strands And Methods For Their Design And Use
Interfering RNA molecules are now designed and produced with specificity for multiple binding sequences present in distinct genetic contexts in one or more pre-selected target RNA molecules and are...
|
|
|
US20090192102 |
miR-21 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-21, using miR-21 to modulate a gene or gene pathway, using this profile in...
|
|
|
US20090192101 |
CANCER-SPECIFIC PROMOTERS
The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the...
|
|
|
US20090192100 |
NOVEL USE OF SPIEGELMERS
The present invention relates to the use of a L-nucleic acid as intracellularly active agent.
|
|
|
US20090192085 |
FKBP-L And Uses Thereof
Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and/or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders...
|
|
|
US20090192084 |
Compositions and method of treating hypoxia-associated diseases
Hypoxia, a state of lower than normal tissue oxygen tension, has recently been implicated in a host of human diseases, including cancer, heart disease, and neurological disorders. Novel...
|
|
|
US20090191259 |
Efficient liposomal encapsulation
The present invention concerns a method for preparing liposomes, said method comprising the following steps: (I) mixing at least one liposome-forming lipid, a water-miscible organic solvent and...
|
|
|
US20090191235 |
CONFORMATIONALLY STABILIZED HIV ENVELOPE IMMUNOGENS AND TRIGGERING HIV-1 ENVELOPE TO REVEAL CRYPTIC V3-LOOP EPITOPES
Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and...
|
|
|
US20090191211 |
METHODS FOR DAMAGING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES
The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions...
|
|
|
US20090191207 |
COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS OR TREATMENT OF VIRAL DISEASES
The invention relates to the use preferably of at least one active ingredient for the prophylaxis or therapy of a viral disease, wherein this active ingredient inhibits at least one component of...
|
|
|
US20090191206 |
Human Semen Enhancer of Viral Infection Peptides (SEVI) and Their Use
Subject of the invention are peptides corresponding to a fragment of amino acids 240-290 of human prostatic acid phosphatase. The invention also relates to nucleic acids, antibodies, medicaments...
|
|
|
US20090191203 |
Bcma Polypeptides And Uses Thereof
The present invention relates to BCMA polypeptide variants and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids...
|
|
|
US20090191194 |
INHIBITION OF PROTEIN KINASE C ALPHA FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
The invention relates to the use of agents impeding the expression and/or activity of protein kinase C-alpha (PKC-α), especially for treatment of patients with diabetes and complications such as...
|
|
|
US20090191185 |
Reducing Cancer Cell Invasion Using an Inhibitor of Toll Like Receptor Signaling
Provided herein are methods and compositions for reducing the invasiveness of cancer cells. Such methods and compositions are particularly useful for cancer cells that express a member of the Toll...
|
|
|
US20090191182 |
Compositions, Kits, and Methods for the Modulation of Immune Responses Using Galectin-1
The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions,...
|
|
|
US20090191176 |
Chondroitin sulfate synthesis promoter
The invention provides a chondroitin sulfate synthesis promoter useful for the treatment of diseases such as articular disease and discopathy. The chondroitin sulfate synthesis promoter contains,...
|
|
|
US20090191170 |
Nucleic acid compositions and methods of introducing nucleic acids into cells
The invention relates to a bifunctional nucleic acid which includes a first nucleic acid which comprises an aptamer bonded to a second nucleic acid that possesses a biological activity (herein...
|
|
|
US20090191156 |
GM-CSF COSMECEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
It has been discovered that granulocyte macrophage colony stimulating factor (“GM-CSF”) promotes migration of activated (but not differentiating) keratinocytes to wound sites. It was also...
|
|
|
US20090191133 |
MODULATION OF STAT 6 EXPRESSION FOR THE TREATMENT OF AIRWAY HYPERRESPONSIVENESS
Disclosed herein are compounds, compositions and methods for modulating the expression of STAT 6 in a cell, tissue, or animal. Also provided are uses of disclosed compounds and compositions in the...
|
|
|
US20090186846 |
Methods to reprogram splice site selection in pre-messenger RNAs
The present invention relates to a method of modulating splice site selection, splicing and alternative, the method comprising the step of hybridizing an oligonucleotide-protein conjugate to a...
|
|
|
US20090186844 |
SiRNA DELIVERY INTO MAMMALIAN NERVE CELLS
The present invention relates to methods of affecting expression of a target gene, suitably brain-derived neurotrophic factor (BDNF) or related genes in a nerve cell in the central nervous system...
|
|
|
US20090186843 |
RNA sequence-specific mediators of RNA interference
The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23...
|
|
|
US20090186842 |
Methods and compositions for inhibition of viral replication
The present invention is directed to methods and compositions that are effective in the inhibition of viral replication. In particular, the methods and compositions are effective at interfering...
|